Bioprocessing and engineering characterisation of T-cell therapy manufacture in an ambr® 250 bioreactor
September 23-26, 2018
The use of engineered CAR-T cells in clinical trials has been growing over the last years. The recent approval of Kymriah® (Novartis) and Yescarta® (KitePharma) made CAR-T cell treatments available to a broader public. However, despite the recent successes and significant improvements, there are different aspects that need to be further assessed in order to develop a reproducible, cost-effective manufacturing process for the production of personalized T-cell therapies. This requires an approach, which generates sufficient quantities of patient-specific cells at the appropriate quality required for clinical application, overcoming the challenge imposed by significantly different starting material.
Please click Additional Files below to see the full abstract.
Qasim Rafiq, Elena Costariol, and Marco Rotondi, "Bioprocessing and engineering characterisation of T-cell therapy manufacture in an ambr® 250 bioreactor" in "Single-Use Technologies III: Scientific and Technological Advancements", Weibing Ding, Amgen Martina Micheletti, University College London Robert Repetto, Pfizer Eds, ECI Symposium Series, (2018). http://dc.engconfintl.org/sut_iii/21